These final results, along with a earlier report demonstrating that a small-molecule ACKR3 agonist CCX771 reveals anxiolytic-like habits in mice,2 guidance the strategy of targeting ACKR3 as a unique way to modulate the opioid method, which could open up new therapeutic avenues for opioid-linked